Bisbenzimidazole derivatives as potent inhibitors of the trypsin-like sites of the immunoproteasome core particle.
Biochimie
; 108: 94-100, 2015 Jan.
Article
in En
| MEDLINE
| ID: mdl-25446655
ABSTRACT
In this study, a monomeric (MB) and a dimeric (DB) bisbenzimidazoles were identified as novel proteasome inhibitors of the trypsin-like activity located on ß2c sites of the constitutive 20S proteasome (IC50 values at 2-4 µM range). Remarkably, they were further shown to be 100- and 200-fold more potent inhibitors of the immunoproteasome trypsin-like activity (ß2i sites, IC50=24 nM) than of the homologous constitutive activity. Molecular models of inhibitor/enzyme complexes in the two types of trypsin-like sites and corresponding computed binding energy values corroborated kinetic data. Different binding modes were suggested for MB and DB to the ß2c and ß2i trypsic sites. Each pointed to better contacts of the ligand inside the ß2i active site than for ß2c site. MB and DB represent the first selective inhibitors of the immunoproteasome trypsin-like activity described to date and can be considered as prototypes for inhibiting this activity.
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Trypsin
/
Catalytic Domain
/
Proteasome Endopeptidase Complex
/
Proteasome Inhibitors
/
Bisbenzimidazole
Limits:
Animals
/
Humans
Language:
En
Year:
2015
Type:
Article